Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder Cancer
نویسندگان
چکیده
Department of Surgery, University of Arizona; BCG Oncology, Phoenix, Arizona, USA Department of Urology/Surgery, Bristol Royal Infirmary & Bristol Urological Institute, Bristol, UK Department of Urology, Claude Bernard University, Hôpital Edouard Herriot, Lyon, France Department of Urology, AUSL Modena Estense and B Ramazzini Hospitals, Modena, Italy E U RO P E AN URO LOG Y SU P P L EM EN T S 9 ( 2 0 1 0 ) 7 1 5 – 7 3 4
منابع مشابه
Challenging the EAU Guidelines on Non–Muscle-Invasive Bladder Cancer (NMIBC): Single Instillation of Chemotherapy After Transurethral Resection of NMIBC and Chemotherapy Versus Bacillus Calmette-Guérin in Treatment of Intermediate-Risk Tumours
Context: Although the 2008 European Association of Urology (EAU) guidelines provide an excellent evidence-based framework for the management of non– muscle-invasive bladder cancer (NMIBC), some topics have been questioned and discussed by many authors and remain controversial. Objective: To comment on the current EAU guidelines on NMIBC by taking into account new data published in 2009 in peer-...
متن کاملCurrent clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international individual patient data survey (IPDS)
OBJECTIVES To examine the management of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC), particularly with regard to the use of bacillus Calmette-Guérin (BCG) therapy, in North America and Europe. To compare NMIBC management practices to European Association of Urology (EAU) and American Urological Association (AUA) guideline recommendations for the management of intermed...
متن کاملTherapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin.
Optimal management of high-risk non-muscle-invasive bladder cancer during the current bacillus Calmette-Guérin (BCG) shortage is challenging. Although no evidence-based guidelines exist for this specific situation, current management options can be adapted for when BCG supplies are limited or when BCG is unavailable.
متن کاملAn individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
BACKGROUND Patients with non-muscle-invasive bladder cancer with an intermediate or high risk need adjuvant intravesical therapy after surgery. Based largely on meta-analyses of previously published results, guidelines recommend using either bacillus Calmette-Guérin (BCG) or mitomycin C (MMC) in these patients. Individual patient data (IPD) meta-analyses, however, are the gold standard. OBJEC...
متن کاملA review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.
PURPOSE Although the European Association of Urology, First International Consultation on Bladder Tumors, National Comprehensive Cancer Network and American Urological Association guidelines all provide an excellent evidence-based framework for the management of nonmuscle invasive bladder cancer, these guidelines vary with respect to important issues such as risk level definitions and managemen...
متن کامل